Used in pharmaceutical research as a potent and selective inhibitor of poly (ADP-ribose) polymerase (PARP), particularly PARP-1 and PARP-2. It is investigated for its role in cancer therapy, especially in tumors with deficiencies in DNA repair pathways such as BRCA-mutated breast and ovarian cancers. The compound enhances the cytotoxic effects of DNA-damaging agents and shows promise in synthetic lethality approaches, where it selectively targets cancer cells while sparing normal tissues. It has been explored in preclinical models for its antitumor activity and pharmacokinetic profile, supporting its development as part of targeted oncology treatments.